Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.
JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.
The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.
JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.
If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.
Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.
JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.
If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at firstname.lastname@example.org. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.
Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.
In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.
This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.
If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: email@example.com.
- Judge Says FDA Can Stop Clinic from Selling Stem Cell ... - May 21st, 2020
- Saad Z. Usmani, on the Approval of Daratumumab and Hyaluronidase-fihj - Cancer Network - May 19th, 2020
- R3 Stem Cell International Now Offering Enhanced Autism Stem Cell Program in Mexico - PR Web - May 19th, 2020
- Stem Cell Concentration System Market Report 2020: Rising Impressive Business - News by aeresearch - May 19th, 2020
- Precision therapy approach secures small biotech $42M haul to combat disease that inspired the Ice Bucket Challenge - Endpoints News - May 19th, 2020
- QurAlis raises $42 Million Series A Financing to Develop New Therapies for Amyotrophic Lateral Sclerosis (ALS) - Business Wire - May 17th, 2020
- Coronavirus Outbreak: Cancer Stem Cell Therapy Market Overview and Competitive Landscape 2020 to 2025 - Cole of Duty - May 15th, 2020
- Intellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the... - May 12th, 2020
- Vasomune Therapeutics Announces Clinical and Scientific Advisory Board - BioSpace - May 12th, 2020
- Orgenesis sees 1Q revenue rocket driven by its Cell and Gene Therapy Biotech platform - Proactive Investors USA & Canada - May 12th, 2020
- Orgenesis First Quarter 2020 Revenue Increases 348% to $1.9 Million Reflecting Success of CGT Biotech Platform - GlobeNewswire - May 12th, 2020
- Meat the Future - documentary Channel - CBC.ca - May 10th, 2020
- Researchers discover stem cells' 'death-defying' quality that aids healing - ETHealthworld.com - May 10th, 2020
- On the Road As a Stem Cell Courier - CSRwire.com - May 3rd, 2020
- You could be someones only hope: A stem cell donor campaigning to beat blood cancer - Evening Standard - May 3rd, 2020
- David C. Karli is Offering a New Ray of Hope Through Regenerative Medicine - RESPECT. - May 3rd, 2020
- FDA Expediting Accelerated Development of Novel Therapies for COVID-19 - PR Newswire UK - May 3rd, 2020
- What to do if you think you have COVID-19: a step by step guide - The Dickinson Press - April 21st, 2020
- Stem cells in the clinic: how are they regulated? - European Pharmaceutical Review - April 20th, 2020
- NHS's oldest IVF clinic at risk of closure amid increasing privatisations - The Guardian - April 20th, 2020
- Here are the drugs that could treat coronavirus. But don't expect a silver bullet. - The Philadelphia Inquirer - April 18th, 2020
- Analyzing the Outcomes With Different Treatment Techniques in Myeloma - Targeted Oncology - April 18th, 2020
- Team to Advance Stem Cell Therapies in New Space Station Lab - Lab Manager Magazine - April 11th, 2020
- Hackensack Meridian Health Studying the Blood of COVID-19 Survivors - P&T Community - April 11th, 2020
- UC San Diego to Advance Stem Cell Therapies in New Space Station Lab - UC San Diego Health - April 9th, 2020
- Orgenesis partners with Belgium"s RevaTis to develop stem cells for therapeutic use - Proactive Investors USA & Canada - April 9th, 2020
- AgeX Therapeutics Reports Fourth Quarter and Annual 2019 Financial Results and Provides Business Update - Yahoo Finance - March 31st, 2020
- Larkhall mum was walked down the aisle by stem cell donor who saved her life - Daily Record - March 31st, 2020
- Q&A: Covid-19 and impact on people with cancer - The Irish Times - March 30th, 2020
- COVID-19 and Cancer: What You Need to Know - Everyday Health - March 30th, 2020
- Cancer Stem Cell Therapy Value Projected to Expand by 2019-2025 - Monroe Scoop - March 27th, 2020
- Unlocking the Potential of a Widely Used Drug - Technology Networks - March 25th, 2020
- Cancer Care and COVID-19 in Seattle, the First US Epicenter - Medscape - March 24th, 2020
- Immatics and Molmed become the subjects of very different deals - Vantage - March 21st, 2020
- Claudia Rodrigues is removed from the clinic where she was hospitalized because of the coronavirus - Crypto Dictation - March 21st, 2020
- Stem cells can reverse damage caused by heart attack; repair mechanism discovered: Study - International Business Times, Singapore Edition - March 16th, 2020
- Newly Discovered Memory in Our Bones: Keeping a Record of Previous Infections to Boost Immunity - SciTechDaily - March 16th, 2020
- The race to find a coronavirus treatment: One strategy might be just weeks away, scientists say - USA TODAY - March 16th, 2020
- Cancer Stem Cell Therapy Market Global Size, Demand-sales, Suppliers by Key Applications 2019 Detailed Analysis and Growth Aspects on Manufacturing... - March 15th, 2020
- Woman meets stranger who saved her life and allowed her to become a mum - Mirror Online - March 15th, 2020
- Stem Cell Manufacturing Market Analysis By Recent Trends, Developments In Top Manufacturing Technology And Regional Growth Overview And Forecast To... - March 11th, 2020
- Kuur Therapeutics Launches to Develop and Commercialize Off-the-shelf CAR-NKT Cell Therapies Targeting Hematological and Solid Tumors | DNA RNA and... - March 11th, 2020
- The London Patient, Cured of H.I.V., Reveals His Identity - The New York Times - March 11th, 2020
- Cancer Stem Cell Therapy Market 2019- Emerging Economies Expected to Influence Growth by 2025 with Major Players-AVIVA BioSciences, AdnaGen, Advanced... - March 10th, 2020
- Maryland Booms in the BioCapital Hotbed - BioSpace - March 10th, 2020
- Gilead to Acquire Immuno-Oncology Company Forty Seven for $4.9 Billion - PharmaLive - March 5th, 2020
- THC Could Be First-of-its-Kind Treatment for Women With Endometriosis, Says New Study - Good News Network - March 5th, 2020
- Autolus Therapeutics Plc (AUTL) QEarnings Call Transcript - Motley Fool - March 5th, 2020
- CytoDyn Treats First Patient with Leronlimab in Phase 2 Trial for GvHD under Modified Trial Protocol - Yahoo Finance - March 5th, 2020
- Magenta Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights - Yahoo Finance - March 4th, 2020
- Omeros Corporation Reports Fourth Quarter and Year-End 2019 Financial Results - Business Wire - March 4th, 2020
- Animal Stem Cell Therapy Market by Segmentation Based on Product, Application and Region, 2019-2025 - Jewish Life News - February 29th, 2020
- Indiana Regenerative Medicine Institute Offers Innovative Approaches in Regenerative Medicine, Hormone Replacement and Pain Management - Zionsville... - February 29th, 2020
- Hyperbaric chamber therapy: Im under a lot of pressure and I love it! - The Guardian - February 25th, 2020
- DDP and Austin Aries Reportedly Pitching Stem Cell Venture to AEW | 411MANIA - 411mania.com - February 25th, 2020
- Why Austin Aries and Raven Were At AEW Dynamite - PWMania - February 25th, 2020
- Austin Aries Confirms Why He Was At AEW Dynamite This Week - 411mania.com - February 24th, 2020
- BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2019 Conference Call and Webcast @ 8:00 am Eastern... - February 18th, 2020
- Animal Stem Cell Therapy Market Projected to Witness Vigorous Expansion by 2017 2025 - Instant Tech News - February 18th, 2020
- 6 Healthcare Stocks That Could Make You Filthy Rich - The Motley Fool - February 18th, 2020
- Mixed ethnic backgrounds make it that much harder to find a bone marrow transplant - MLive.com - February 17th, 2020
- 48% of Couples Are Making This Financial Mistake - Nasdaq - February 17th, 2020
- 'Loving life': 4-year-old not letting heart condition slow him down - Port Clinton News Herald - February 15th, 2020
- Cancer Stem Cell Therapy Market Trends, Key Players, Overview, Competitive Breakdown and Regional Forecast by 2025 Mathematics Market Methods - Keep... - February 15th, 2020
- Regenexx, First to Use Stem Cells in Orthopedic Therapy, Marks 15th Anniversary - Yahoo Finance - February 12th, 2020
- What Drives the Domino Effect in Cancer Drug Resistance? - Technology Networks - February 12th, 2020
- CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019 - Xconomy - February 12th, 2020
- Science team designs a new CAR they say may work much better than BCMAs in fighting multiple myeloma - Endpoints News - February 12th, 2020
- Omeros: 2 Major Catalysts On The Horizon - Seeking Alpha - February 10th, 2020
- Blood In The Joint - Economic Times - February 10th, 2020
- PRACTICALLY ACTIVE: Screening is a smart way to start a healthier life - NWAOnline - February 10th, 2020
- Anemia: Causes, symptoms and treatment - Livescience.com - February 6th, 2020
- Here's Why CRISPR Stocks Fell in January - The Motley Fool - February 6th, 2020
- Victoria Beckham says this product is the best product you will ever use - Marie Claire UK - February 6th, 2020
- Korzan: On World Cancer day, pledge to be relentless - AberdeenNews.com - February 5th, 2020
- Global Radiation Therapy Market to Reach US$ 8.6 bn by 2026, Product Approvals to Drive Growth: Transparency Market Research - PRNewswire - February 5th, 2020
- SASpine to offer Stem Cell Therapy - Yahoo Finance - February 4th, 2020
- Dr. Kenneth Pettine Announces Verification of Clinical Safety Trial - Yahoo Finance - February 4th, 2020
- The Marsh Presents Welcome to The Cancer Caf - Patch.com - February 4th, 2020
- Freeport stem cell therapy provider Okyanos in wind-up petition battle - EyeWitness News - February 4th, 2020